Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | VCP | P55072 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 11/20 | 0.45 |
| ▸ | MAOB | P27338 | 11/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088254 | 1.00 | KDM4E (0.53) | KDM4EKMT2AMEN1MAPTGAA | |
| SCHEMBL3525480 | 0.83 | KDM4E (0.53) | KDM4EKMT2AMEN1MAPTGAA | |
| Bromide SCHEMBL4509188 | 0.77 | VCP (0.53) | KDM4EKMT2AMEN1MAPTGAA | |
| SCHEMBL3175801 | 0.76 | VCP (0.58) | KDM4EKMT2AMEN1MAPTGAA | |
| SCHEMBL10918876 | 0.74 | KDM4E (0.74) | KDM4EKMT2AMEN1MAPTGAA | |
| SCHEMBL4078495 | 0.74 | KDM4E (0.51) | KDM4EKMT2AMEN1MAPTGAA | |
| SCHEMBL5381785 | 0.74 | VCP (0.55) | KDM4EKMT2AMEN1MAPTGAA | |
| SCHEMBL2579091 | 0.72 | GAA (0.64) | KDM4EKMT2AMEN1MAPTGAA | |
| SCHEMBL3166865 | 0.72 | MAOA (0.54) | KDM4EKMT2AMEN1MAPTGAA | |
| SCHEMBL4074331 | 0.72 | KDM4E (0.48) | KDM4EKMT2AMEN1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045560-A1 | Pyrrolidine and related derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008021339-A2 | PYRROLIDINE AND RELATED DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045560-A1 | Pyrrolidine and related derivatives useful as PR modulators | PRLHR, GNRHR, NPY1R | KDM4E 563/4885KMT2A 492/4885MEN1 135/4885 |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | MC2R, NPY1R, PRLHR | KDM4E 480/4885KMT2A 667/4885MEN1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.